NASDAQ:ALEC Alector (ALEC) Stock Price, News & Analysis $3.76 +0.12 (+3.30%) (As of 11/21/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Alector Stock (NASDAQ:ALEC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Alector alerts:Sign Up Key Stats Today's Range$3.49▼$3.8050-Day Range$3.64▼$6.1452-Week Range$3.49▼$8.90Volume789,738 shsAverage Volume626,728 shsMarket Capitalization$368.22 millionP/E RatioN/ADividend YieldN/APrice Target$20.67Consensus RatingBuy Company OverviewAlector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.Read More… What Comes Next Could Be a Once-in-a-Lifetime Opportunity (Ad)A wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.Click here now to watch the full briefing and discover the steps to take today. Alector Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreALEC MarketRank™: Alector scored higher than 88% of companies evaluated by MarketBeat, and ranked 143rd out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAlector has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAlector has only been the subject of 2 research reports in the past 90 days.Read more about Alector's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Alector are expected to grow in the coming year, from ($1.87) to ($1.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alector is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Alector is -2.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAlector has a P/B Ratio of 3.11. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Alector's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted6.24% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Alector has recently decreased by 3.09%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAlector does not currently pay a dividend.Dividend GrowthAlector does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-0.92 Percentage of Shares Shorted6.24% of the float of Alector has been sold short.Short Interest Ratio / Days to CoverAlector has a short interest ratio ("days to cover") of 8.8.Change versus previous monthShort interest in Alector has recently decreased by 3.09%, indicating that investor sentiment is improving. News and Social Media3.4 / 5News SentimentN/A News SentimentAlector has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Alector this week, compared to 2 articles on an average week.Search Interest1 people have searched for ALEC on MarketBeat in the last 30 days. MarketBeat Follows2 people have added Alector to their MarketBeat watchlist in the last 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Alector insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $232,883.00 in company stock.Percentage Held by InsidersOnly 9.10% of the stock of Alector is held by insiders.Percentage Held by Institutions85.83% of the stock of Alector is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Alector's insider trading history. Receive ALEC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alector and its competitors with MarketBeat's FREE daily newsletter. Email Address ALEC Stock News HeadlinesAlector Secures Funding to Advance Clinical TrialsNovember 15, 2024 | markets.businessinsider.comAlector Secures Flexible Credit Facility for Up to $50 Million From Hercules CapitalNovember 14, 2024 | globenewswire.comWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who understand the shifts ahead, this could be the foundation for long-term wealth creation. In this exclusive briefing, I'll show you exactly how to prepare for the challenges and opportunities ahead. You'll learn actionable strategies to protect your portfolio and position yourself for growth in the months and years to come.November 22, 2024 | InvestorPlace (Ad)Stifel Nicolaus Sticks to Its Buy Rating for Alector (ALEC)November 9, 2024 | markets.businessinsider.comPromising Developments in Alector’s Alzheimer’s Treatments Drive Buy RatingNovember 7, 2024 | markets.businessinsider.comAlector’s Promising Phase 2 Study and Strong Financial Outlook Justify Buy RatingNovember 7, 2024 | markets.businessinsider.comAlector Reports Third Quarter 2024 Financial Results and Provides Business UpdateNovember 6, 2024 | globenewswire.comIs Alector (NASDAQ:ALEC) In A Good Position To Deliver On Growth Plans?October 30, 2024 | finance.yahoo.comSee More Headlines ALEC Stock Analysis - Frequently Asked Questions How have ALEC shares performed this year? Alector's stock was trading at $7.98 on January 1st, 2024. Since then, ALEC stock has decreased by 52.9% and is now trading at $3.76. View the best growth stocks for 2024 here. How were Alector's earnings last quarter? Alector, Inc. (NASDAQ:ALEC) issued its quarterly earnings data on Wednesday, November, 6th. The company reported ($0.43) EPS for the quarter, topping analysts' consensus estimates of ($0.53) by $0.10. The business earned $15.34 million during the quarter, compared to the consensus estimate of $16.33 million. Alector had a negative net margin of 257.54% and a negative trailing twelve-month return on equity of 108.77%. Does Alector have any subsidiaries? Alector subsidiaries include Alector LLC. When did Alector IPO? Alector (ALEC) raised $177 million in an initial public offering (IPO) on Thursday, February 7th 2019. The company issued 9,300,000 shares at $18.00-$20.00 per share. Morgan Stanley, BofA Merrill Lynch, Cowen and Barclays served as the underwriters for the IPO. Who are Alector's major shareholders? Top institutional shareholders of Alector include FMR LLC (14.90%), State Street Corp (2.67%), Braidwell LP (2.20%) and Geode Capital Management LLC (1.94%). Insiders that own company stock include Polaris Venture Management Co, Arnon Rosenthal, Robert King, Sara Kenkare-Mitra, Gary Romano, Marc Grasso, Paula Hammond and Shehnaaz Suliman. View institutional ownership trends. How do I buy shares of Alector? Shares of ALEC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Alector own? Based on aggregate information from My MarketBeat watchlists, some other companies that Alector investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Enovix (ENVX), Meta Platforms (META), Rambus (RMBS), Saia (SAIA) and Tesla (TSLA). Company Calendar Last Earnings11/06/2024Today11/21/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/25/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALEC CUSIPN/A CIK1653087 Webwww.alector.com Phone(415) 231-5660FaxN/AEmployees270Year Founded2013Price Target and Rating Average Stock Price Target$20.67 High Stock Price Target$35.00 Low Stock Price Target$12.00 Potential Upside/Downside+449.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.70) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-130,390,000.00 Net Margins-257.54% Pretax Margin-254.70% Return on Equity-108.77% Return on Assets-27.03% Debt Debt-to-Equity RatioN/A Current Ratio3.29 Quick Ratio3.29 Sales & Book Value Annual Sales$97.06 million Price / Sales3.79 Cash FlowN/A Price / Cash FlowN/A Book Value$1.21 per share Price / Book3.11Miscellaneous Outstanding Shares97,930,000Free Float89,021,000Market Cap$368.22 million OptionableOptionable Beta0.66 Social Links Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:ALEC) was last updated on 11/22/2024 by MarketBeat.com Staff From Our Partners[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredCentral Bank Abandons USDYou know what doesn't care about elections? Gold. If you want to protect your savings & retirement from our...Desko Digital | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredWhat Comes Next Could Be a Once-in-a-Lifetime OpportunityA wave of technological and financial transformation is reshaping the investment landscape. For those who unde...InvestorPlace | SponsoredAre Your Retirement Savings Really Safe?What They Don’t Want You to Know About Your 401(k)The 2008-2010 crisis wiped out almost 50% of the value of retirement funds. If you knew it was coming, wouldn'...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alector, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alector With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.